Inmune Bio, Inc. (INMB) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.4	0.2	0.0	9.3	0.0	0.0
Revenue growth	106.6%	1545.5%	-99.9%
Cost of goods sold	0.0	-30.5	-13.1	0.0	0.0	-1.1
Gross profit	0.4	30.7	13.1	9.3	0.0	1.1
Gross margin	100.0%	16961.3%	119281.8%	100.0%
Selling, general and administrative [+]	9.3	8.8	6.3	6.0	9.1	0.5
General and administrative	9.3	8.8	6.3	6.0	9.1	0.5
Research and development	17.1	20.5	5.9	3.3	3.4	0.4
Other operating expenses	0.0	28.1	12.4	7.8		1.0
EBIT [+]	-25.9	-26.8	-11.5	-7.8	-12.4	-0.8
EBIT growth	-3.2%	133.2%	48.1%	-37.7%	1396.1%
EBIT margin	-6934.0%	-14796.1%	-104418.2%	-83.4%
Non-recurring items [+]	0.0	2.4	0.7			0.2
Legal settlement						0.2
Interest expense	2.0	1.0
Other income (expense), net [+]	0.7	-0.2	0.1	0.1		0.1
Other non-operating income				0.1
Other non-ooperating expenses						0.0
Other				0.1
Pre-tax income	-27.3	-30.3	-12.1	-7.7	-12.4	-0.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-27.3	-30.3	-12.1	-7.7	-12.4	-0.8
Net margin	-7299.2%	-16762.4%	-109990.9%	-82.6%

Basic EPS [+]	($1.52)	($1.88)	($1.01)	($0.75)	($1.43)	($0.13)
Growth	-19.0%	86.4%	35.0%	-47.9%	1031.9%
Diluted EPS [+]	($1.52)	($1.88)	($1.01)	($0.75)	($1.43)	($0.13)
Growth	-19.0%	86.4%	35.0%	-47.9%	1031.9%

Shares outstanding (basic) [+]	17.9	16.1	12.0	10.3	8.7	6.6
Growth	11.1%	34.6%	16.7%	18.4%	32.2%
Shares outstanding (diluted) [+]	17.9	16.1	12.0	10.3	8.7	6.6
Growth	11.1%	34.6%	16.7%	18.4%	32.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.